Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Table 6 Cox’s proportional hazard multivariate regression analysis assessing the factors contributing to the incidence of refractory ascites
| Variables | HR (95%CI) | P |
| Use of TLV | 0.58 (0.39-0.87) | < 0.01 |
| Age (yr) | 1.01 (0.99-1.03) | 0.19 |
| Uncontrollable liver neoplasms | 1.92 (1.23-2.94) | < 0.01 |
| ALT (IU/L) | 1.00 (0.98-1.01) | 0.11 |
| Total bilirubin (mg/dL) | 1.10 (1.03-1.18) | < 0.01 |
| Na (mEq/mL) | 0.94 (0.91-0.98) | < 0.01 |
- Citation: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1685